Literature DB >> 26536055

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.

Suzanne M Crumley1, Kristi L Pepper1, Alexandria T Phan1, Randall J Olsen1, Mary R Schwartz1, Bryce P Portier1.   

Abstract

CONTEXT: -Colorectal carcinoma is the third most common cause of cancer death in males and females in the United States. Rectal adenocarcinoma can have distinct therapeutic and surgical management from colonic adenocarcinoma owing to its location and anatomic considerations.
OBJECTIVE: -To determine the oncologic driver mutations and better understand the molecular pathogenesis of rectal adenocarcinoma in relation to colon adenocarcinoma.
DESIGN: -Next-generation sequencing was performed on 20 cases of primary rectal adenocarcinoma with a paired lymph node or solid organ metastasis by using an amplicon-based assay of more than 2800 Catalogue of Somatic Mutations in Cancer (COSMIC)-identified somatic mutations.
RESULTS: -Next-generation sequencing data were obtained on both the primary tumor and metastasis from 16 patients. Most rectal adenocarcinoma cases demonstrated identical mutations in the primary tumor and metastasis (13 of 16, 81%). The mutations identified, listed in order of frequency, included TP53, KRAS, APC, FBXW7, GNAS, FGFR3, BRAF, NRAS, PIK3CA, and SMAD4.
CONCLUSIONS: -The somatic mutations identified in our rectal adenocarcinoma cohort showed a strong correlation to those previously characterized in colonic adenocarcinoma. In addition, most rectal adenocarcinomas harbored identical somatic mutations in both the primary tumor and metastasis. These findings demonstrate evidence that rectal adenocarcinoma follows a similar molecular pathogenesis as colonic adenocarcinoma and that sampling either the primary or metastatic lesion is valid for initial evaluation of somatic mutations and selection of possible targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26536055     DOI: 10.5858/arpa.2015-0261-SA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Authors:  Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2019-02-13       Impact factor: 4.481

2.  KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.

Authors:  Mariana Petaccia de Macedo; Fernanda M Melo; Heber Salvador C Ribeiro; Marcio C Marques; Luciane T Kagohara; Maria Dirlei Begnami; Julio C Neto; Júlia S Ribeiro; Fernando A Soares; Dirce M Carraro; Isabela W Cunha
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

3.  Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  In Hee Lee; Keunsoo Kang; Byung Woog Kang; Soo Jung Lee; Woo Kyun Bae; Jun Eul Hwang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  Med Oncol       Date:  2018-09-11       Impact factor: 3.064

4.  Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery.

Authors:  Thomas Schweiger; Sandra Liebmann-Reindl; Olaf Glueck; Patrick Starlinger; Johannes Laengle; Peter Birner; Walter Klepetko; Dietmar Pils; Berthold Streubel; Konrad Hoetzenecker
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

5.  Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.

Authors:  Elena Fountzilas; Vassiliki Kotoula; Ioannis Tikas; Kyriaki Manousou; Kyriaki Papadopoulou; Christos Poulios; Vasilios Karavasilis; Ioannis Efstratiou; Dimitrios Pectasides; Kleo Papaparaskeva; Ioannis Varthalitis; Christos Christodoulou; George Papatsibas; Sofia Chrisafi; Georgios K Glantzounis; Amanda Psyrri; Gerasimos Aravantinos; Georgia-Angeliki Koliou; George K Koukoulis; George E Pentheroudakis; George Fountzilas
Journal:  Oncotarget       Date:  2018-11-02

6.  Biomarker concordance between primary colorectal cancer and its metastases.

Authors:  D S Bhullar; J Barriuso; S Mullamitha; M P Saunders; S T O'Dwyer; O Aziz
Journal:  EBioMedicine       Date:  2019-02-04       Impact factor: 8.143

7.  Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.

Authors:  Shinkyo Yoon; Miso Kim; Yong Sang Hong; Han Sang Kim; Seung Tae Kim; Jihun Kim; Hongseok Yun; Changhoon Yoo; Hee Kyung Ahn; Hyo Song Kim; In Hee Lee; In-Ho Kim; Inkeun Park; Jae Ho Jeong; Jaekyung Cheon; Jin Won Kim; Jina Yun; Sun Min Lim; Yongjun Cha; Se Jin Jang; Dae Young Zang; Tae Won Kim; Jin Hyoung Kang; Jee Hyun Kim
Journal:  Cancer Res Treat       Date:  2021-12-13       Impact factor: 4.679

8.  Recommendations for Specimen and Therapy Selection in Colorectal Cancer.

Authors:  Snehal B Patel; Robert Bookstein; Navid Farahani; Myriam Chevarie-Davis; Andy Pao; Angela Aguiluz; Christian Riley; Jennelle C Hodge; Serhan Alkan; Zhenqui Liu; Nan Deng; Jean R Lopategui
Journal:  Oncol Ther       Date:  2021-04-25

9.  Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.

Authors:  Valentina Kovaleva; Anna-Lena Geissler; Lisa Lutz; Ralph Fritsch; Frank Makowiec; Sebastian Wiesemann; Ulrich T Hopt; Bernward Passlick; Martin Werner; Silke Lassmann
Journal:  Mol Cancer       Date:  2016-10-18       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.